Biotech Firms Shift AI Drug R&D to Lab Validation
Pharmaceutical companies have prioritized empirical testing to verify AI-driven drug candidates.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to successfully develop new medicines using artificial intelligence?
Pharmaceutical firms have pivoted their AI drug discovery strategies to focus on rigorous lab validation of compounds. The industry reached $45.9 billion in total AI R&D deal values during the first half of 2026.
Why it matters
The industry emphasis has shifted toward physical validation because AI algorithms can provide incorrect results during the virtual drug discovery process. Companies are now looking to prove the clinical viability of candidates generated by these computational models.
Novorex synthesized 186 compounds for its Parkinson's candidate, NRX-NGT002, significantly reducing the 2,000 compounds typically required by conventional methods. The identification process for this candidate was completed in 18 months.
The players
Novorex
This is a biotech company that focuses on using artificial intelligence to accelerate the identification and development of drug candidates.
SK Biopharmaceuticals
This global pharmaceutical firm specializes in the development of treatments for central nervous system disorders.
Portrai
This company develops AI technology for the identification of drug targets using tumor tissue mapping.
Celltrion
This is a biopharmaceutical company that conducts research, development, and manufacturing of biosimilar and innovative medicines.
Novo Nordisk
This global healthcare company is focused on driving change to defeat diabetes and other serious chronic diseases.
The details
Researchers are utilizing E. coli and other organisms to create disease-associated proteins to test compound binding. Additionally, firms like Portrai are scanning tumor tissue maps and checking targets against patient data to improve selection accuracy.
Timeline
April 2026: SK Biopharmaceuticals partnered with Novorex.
H1 2026: AI drug R&D partnership deal values reached $45.9 billion.
Q2 2026: Median upfront payments for R&D deals fell to $15 million.
September 10, 2026: Novorex researchers tested AI-selected drug candidates.
Year-end 2026: Novorex targets the start of global clinical trials.
The Tech Race
The adoption of the Claude Science model illustrates how large language models are being integrated into the pharmaceutical R&D pipeline to automate target identification. This represents a structural shift from legacy manual screening to AI-augmented discovery workflows.
The transition to AI-accelerated drug discovery could eventually shorten the time patients wait for life-saving treatments for complex diseases like Parkinson's. However, the current focus on validation means consumers may see fluctuating costs as companies adjust their R&D budget models.
The takeaway
While AI is rapidly shortening the time required to identify promising drug compounds, successful medical outcomes still rely on the proven reliability of traditional lab testing. Investors and patients should view AI-driven pipelines as a tool for acceleration rather than a total replacement for clinical proof.
What happens next
Novorex plans to initiate global clinical trials for its AI-discovered Parkinson's candidate by the end of 2026.
Further reading
Learn more about the latest innovations in Biotech.
Source note: This article includes information reported by Koreajoongangdaily.
Live Poll
Do you trust pharmaceutical companies to successfully develop new medicines using artificial intelligence?
